2020-22403. Wockhardt Ltd., et al.; Withdrawal of Approval of Nine Abbreviated New Drug Applications  

  • Start Preamble Start Printed Page 64150

    AGENCY:

    Food and Drug Administration, HHS.

    ACTION:

    Notice.

    SUMMARY:

    The Food and Drug Administration (FDA or Agency) is withdrawing approval of nine abbreviated new drug applications (ANDAs) from multiple applicants. The applicants notified the Agency in writing that the drug products were no longer marketed and requested that the approval of the applications be withdrawn.

    DATES:

    Approval is withdrawn as of November 9, 2020.

    Start Further Info

    FOR FURTHER INFORMATION CONTACT:

    Martha Nguyen, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 75, Rm. 1676, Silver Spring, MD 20993-0002, 240-402-6980, Martha.Nguyen@fda.hhs.gov.

    End Further Info End Preamble Start Supplemental Information

    SUPPLEMENTARY INFORMATION:

    The applicants listed in the table have informed FDA that these drug products are no longer marketed and have requested that FDA withdraw approval of the applications under the process described in § 314.150(c) (21 CFR 314.150(c)). The applicants have also, by their requests, waived their opportunity for a hearing. Withdrawal of approval of an application or abbreviated application under § 314.150(c) is without prejudice to refiling.

    Application No.DrugApplicant
    ANDA 040533Bethanechol Chloride Tablets, 10 milligrams (mg)Morton Grove Pharmaceuticals Inc./Wockhardt USA LLC, 6451 Main St., Morton Grove, IL 60053.
    ANDA 040534Bethanechol Chloride Tablets, 25 mgDo.
    ANDA 075015Acyclovir Sodium for Injection, Equivalent to (EQ) 500 mg base/vialFresenius Kabi USA, LLC, Three Corporate Dr., Lake Zurich, IL 60047.
    ANDA 075773Pamidronate Disodium for Injection, 30 mg/vial, and 90 mg/vialDo.
    ANDA 076206Calcitriol Injection, 0.001 mg/milliliter (mL)Rockwell Medical, Inc., 30142 S. Wixom Rd., Wixom, MI 48393.
    ANDA 076207Pamidronate Disodium Injection, 30 mg/10 mL (3 mg/mL) and 90 mg/mL (9 mg/mL)Fresenius Kabi USA, LLC.
    ANDA 077788Albuterol Sulfate Syrup, EQ 2 mg base/5 mLVistaPharm, Inc., 7265 Ulmerton Rd., Largo, FL 33771.
    ANDA 077990Zolpidem Tartrate Tablets, 5 mg and 10 mgCarlsbad Technology, Inc., U.S. Agent for Yung Shin Pharmaceutical Industrial Co., Ltd., 4761 Tara Ct., West Bloomfield, MI 48323.
    ANDA 202410Donepezil Hydrochloride Tablets, 23 mgHisun Pharmaceutical (Hangzhou) Co., Ltd., U.S. Agent, Hisun Pharmaceuticals USA, Inc., 200 Crossing Blvd., 2nd floor, Bridgewater, NJ 08807.

    Therefore, approval of the applications listed in the table, and all amendments and supplements thereto, is hereby withdrawn as of November 9, 2020. Approval of each entire application is withdrawn, including any strengths and dosage forms inadvertently missing from the table. Introduction or delivery for introduction into interstate commerce of products without approved new drug applications violates section 301(a) and (d) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 331(a) and (d)). Drug products that are listed in the table that are in inventory on November 9, 2020 may continue to be dispensed until the inventories have been depleted or the drug products have reached their expiration dates or otherwise become violative, whichever occurs first.

    Start Signature

    Dated: October 5, 2020.

    Lauren K. Roth,

    Acting Principal Associate Commissioner for Policy.

    End Signature End Supplemental Information

    [FR Doc. 2020-22403 Filed 10-8-20; 8:45 am]

    BILLING CODE 4164-01-P

Document Information

Published:
10/09/2020
Department:
Food and Drug Administration
Entry Type:
Notice
Action:
Notice.
Document Number:
2020-22403
Dates:
Approval is withdrawn as of November 9, 2020.
Pages:
64150-64150 (1 pages)
Docket Numbers:
Docket No. FDA-2020-N-1866
PDF File:
2020-22403.pdf
Supporting Documents:
» Wockhardt Ltd., et al.; Withdrawal of Approval of Nine Abbreviated New Drug Applications; Correction
» Wockhardt Ltd., et al.; Withdrawal of Approval of Nine Abbreviated New Drug Applications